이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Niacin and Selenium Combination Therapy in Patients With Septic Shock (NISE-1)

2026년 11월 10일 업데이트: Woon Yong Kwon, Seoul National University Hospital

Combination Therapy of Niacin and Selenium in Patients With Septic Shock (Phase IIa Single Center Double-blind Randomized Controlled Trial)

This study will test whether adding niacin, a form of vitamin B3, and selenium, a mineral, to standard treatment improves organ function in adults with septic shock. It will also assess the safety of this combination.

The study plans to enroll 148 patients aged 19 years or older in the emergency intensive care unit at Seoul National University Hospital in South Korea. Participants will be assigned by chance to one of two groups, with an equal chance of receiving either niacin plus selenium or placebo infusions. The placebo infusions use saline and glucose (sugar) solutions and do not contain the study drugs. All participants will receive standard treatment for septic shock.

Study treatments will be given through a vein twice a day during the first week of hospitalization. Participants and the researchers assessing outcomes will not know which treatment each participant receives. The study pharmacist and a designated team that prepares and gives the infusions will know the treatment assignments.

The main comparison will be organ function on the seventh day of hospitalization, measured using the Sequential Organ Failure Assessment (SOFA) score. This score measures how well several organs are working. Researchers will also compare survival at 28 and 90 days, time spent in intensive care, and time on a breathing machine. Blood samples will be collected at enrollment, approximately 72 hours later, and on study day 7 to measure niacin and selenium levels and biomarkers related to antioxidant activity and oxidative stress. Possible side effects will be monitored through daily assessments and blood tests.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Oxidative stress and dysregulated inflammatory responses contribute to tissue injury and organ dysfunction in septic shock. The rationale for combining niacin and selenium is to enhance intracellular antioxidant defenses through complementary effects on the glutathione redox cycle.

Preclinical experiments showed that niacin increased glutathione reductase activity and selenium increased glutathione peroxidase activity. Combined treatment reduced hydrogen peroxide levels, attenuated lung injury, and improved survival in rat models of sepsis. These findings provide a biological basis for evaluating the combination as an adjunctive treatment in patients with septic shock.

The study hypothesis is that combined niacin and selenium treatment during the acute phase of septic shock may reduce oxidative and inflammatory injury and thereby limit organ dysfunction. This study is intended to provide preliminary clinical evidence on efficacy and safety and to inform the planning of a subsequent multicenter trial.

연구 유형

중재적

등록 (추정된)

148

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: WOON YONG KWON, MD, PhD
  • 전화번호: 82-2-2072-0326
  • 이메일: kwy711@hanmail.net

연구 연락처 백업

  • 이름: Hayoung Kim, MD, PhD
  • 전화번호: 82-2-2072-3257
  • 이메일: mogu13@naver.com

연구 장소

      • Seoul, 대한민국, 03080
        • Seoul National University Hospital
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • WOON YONG KWON, MD, PhD

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

19년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Age 19 years or older, irrespective of sex or race.
  • Admission to the emergency intensive care unit at Seoul National University Hospital with septic shock, defined by all of the following:

Infection-related organ dysfunction with a Sequential Organ Failure Assessment (SOFA) score of 2 or greater.

Sepsis-induced hypotension requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or higher.

A blood lactate concentration of 2 mmol/L or higher despite administration of 30 mL/kg of intravenous crystalloid fluid. If this volume cannot be administered because of pulmonary edema, heart failure, chronic renal failure, or other clinical limitations, the maximum clinically tolerated volume of crystalloid fluid must have been administered.

Written informed consent provided by the participant or an authorized representative.

Informed consent and randomization completed within 24 hours after the diagnosis of septic shock.

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Age younger than 19 years.
  • Cardiac arrest requiring cardiopulmonary resuscitation before admission to the emergency intensive care unit.
  • Expected death within 72 hours because of the severity of illness.
  • Patients for whom aggressive treatment is not being provided in accordance with an advance directive.
  • Known pre-existing liver failure with a Child-Pugh score of 10 or greater.
  • Lack of informed consent from the participant or an authorized representative.
  • Any other condition or circumstance that, in the investigator's judgment, makes participation in the trial inappropriate.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 네 배로

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Niacin plus Selenium

Participants receive intravenous niacin plus selenium every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.

Niacin (nicotinic acid) is supplied by Christmas Co., Ltd. (South Korea) as V-Tree Inj., a solution for injection containing 50 mg of niacin per 1 mL ampoule. A dose of 100 mg will be diluted with 0.9% sodium chloride solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

Selenium is supplied as selenase T pro injectione (biosyn Arzneimittel GmbH, Germany), a solution for injection containing 500 micrograms of selenium as sodium selenite pentahydrate per 10 mL vial (50 micrograms/mL). A dose of 5 micrograms/kg of selenium will be diluted with 5% dextrose solution to a final volume of 50 mL and administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

위약 비교기: Placebo

Participants receive intravenous placebo infusions of 0.9% sodium chloride and 5% dextrose every 12 hours during the first week of hospitalization, in addition to standard care for septic shock.

Participants receive 50 mL of 0.9% sodium chloride solution as the placebo for niacin. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

Participants receive 50 mL of 5% dextrose solution as the placebo for selenium. The solution is administered by intravenous infusion over 1 hour every 12 hours during the first week of hospitalization.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Sequential Organ Failure Assessment (SOFA) Score on Hospital Day 7
기간: Hospital day 7

Total Sequential Organ Failure Assessment (SOFA) score assessed on hospital day 7. The SOFA score evaluates six organ systems: respiratory, coagulation, liver, cardiovascular, central nervous system, and renal. Each component is scored from 0 to 4, giving a total score of 0 to 24; higher scores indicate more severe organ dysfunction. The day-7 score will be compared between groups using analysis of covariance, with adjustment for the SOFA score at admission.

Hospital day 7

2차 결과 측정

결과 측정
측정값 설명
기간
28-Day Survival
기간: From hospital admission (hospital day 0) through day 28

Survival will be assessed from hospital admission, defined as hospital day 0, through day 28. The probability of survival at day 28 will be estimated using the Kaplan-Meier method.

From hospital admission (hospital day 0) through day 28
90-Day Survival
기간: From hospital admission (hospital day 0) through day 90

Survival will be assessed from hospital admission, defined as hospital day 0, through day 90. The probability of survival at day 90 will be estimated using the Kaplan-Meier method.

From hospital admission (hospital day 0) through day 90
Length of Intensive Care Unit Stay
기간: From hospital admission (hospital day 0) through hospital day 90

Length of stay in the intensive care unit, measured in days, during follow-up through hospital day 90.

From hospital admission (hospital day 0) through hospital day 90
Duration of Mechanical Ventilation
기간: From hospital admission (hospital day 0) through hospital day 90

Duration of mechanical ventilation, measured in days, during follow-up through hospital day 90.

From hospital admission (hospital day 0) through hospital day 90

기타 결과 측정

결과 측정
측정값 설명
기간
Pharmacologic, Antioxidant, and Mechanistic Biomarkers
기간: At enrollment, 72 hours (±6 hours), and day 7

Blood samples will be analyzed to assess the biological effects of niacin and selenium treatment, including circulating niacin and selenium levels and biomarkers related to antioxidant activity, redox balance, and oxidative stress. Planned analyses include glutathione reductase activity, glutathione peroxidase activity, and hydrogen peroxide levels.

At enrollment, 72 hours (±6 hours), and day 7

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: WOON YONG KWON, MD, PhD, Seoul National University Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 16일

기본 완료 (추정된)

2028년 4월 30일

연구 완료 (추정된)

2028년 7월 31일

연구 등록 날짜

최초 제출

2026년 11월 10일

QC 기준을 충족하는 최초 제출

2026년 11월 10일

처음 게시됨 (실제)

2026년 11월 17일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 17일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 10일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • SNUH-NISE-2026
  • 2509-096-1679 (기타 식별자: Seoul National University Hospital Institutional Review Board)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data that underlie the results reported in the primary publication may be shared with qualified researchers upon reasonable request, subject to review and approval by the principal investigator and applicable institutional and ethical requirements. Data will be shared only in a manner that protects participant confidentiality and privacy.

IPD 공유 기간

De-identified individual participant data and supporting information will be available beginning 6 months after publication of the primary study results and for 3 years thereafter.

IPD 공유 액세스 기준

De-identified individual participant data that underlie the results reported in the primary publication, together with the study protocol and statistical analysis plan, may be made available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the principal investigator and must comply with applicable institutional and ethical requirements. Approved data will be provided through a secure data-sharing method after execution of any required data use agreement.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .